Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inactivated Akkermansia muciniphila (Akk11) plus metformin in obese women with PCOS
ChiCTR2600124649Phase 4Not yet recruiting
- Sponsor
- Shanghai East Hospital
- Start
- May 2026
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial in polycystic ovary syndrome (PCOS) comparing Akk11 + metformin with Control: placebo + metformin (2 arms). Primary endpoint: HOMA-IR (insulin resistance index) at week 12. Planned start May 2026; status: not yet recruiting.
02
Drugs
inactivated Akkermansia muciniphila
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on ChiCTR2600124649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124649.